Compugen has reported new and promising results from studies on animal models of multiple sclerosis (MS) that support its lead drug candidate, CGEN-15001, as a potential treatment for a variety of autoimmune diseases, including MS. Read on.
Fusion Protein, CGEN-15001, Shows Ability to Restore Immune Balance in Mice with MS